Marrs Anna, Group President of GCS and CFR, has filed 41 Form 4 transactions across two companies, with a pronounced sell-side bias. Over the reporting period, she recorded zero open-market purchases and approximately $25.5 million in total sales, while acquiring about $14.2 million in shares—almost entirely through option exercises and equity awards rather than discretionary buys. The most recent activity, spanning June 2026, shows a consistent pattern: small open-market sales of DOCU stock on June 5 ($17,939), June 2 ($20,089), and March 5 ($16,817), each paired with option exercises (coded M) that carried no transaction value. These recurring sales, typically in the $16,000–$25,000 range, appear tied to scheduled vesting events rather than a concentrated divestment.
The larger dollar figures come from American Express (AXP), where Marrs executed a $9.6 million open-market sale on February 5, 2026, alongside a $2.6 million option exercise on the same day. That sale was preceded by a series of February 1 equity grants (coded A) and tax-withholding dispositions (coded F) totaling roughly $5.1 million, suggesting the sale offset newly vested compensation. A prior AXP sale on July 29, 2025, brought in $1.7 million. Across both tickers, the data shows no outright purchases—only sales, exercises, grants, and automatic tax-related withholdings—indicating Marrs is monetizing equity rather than adding exposure.
The trajectory is consistent: DOCU sales occur in small, routine increments following each vesting period, while AXP transactions are larger and less frequent, clustered around annual grant dates. The absence of any P-coded buys, combined with the mechanical nature of M and F codes, points to a portfolio management strategy centered on liquidity, not a directional bet on either stock. Total sell value of $25.5 million versus zero discretionary purchases underscores a clear net reduction in holdings over the observed window.
AI-assisted summary